Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 1,372 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube sold 1,372 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $16,710.96. Following the transaction, the chief accounting officer now owns 45,640 shares in the company, valued at $555,895.20. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $12.47 on Wednesday. Intellia Therapeutics, Inc. has a 52 week low of $11.34 and a 52 week high of $34.87. The firm has a market cap of $1.27 billion, a P/E ratio of -2.29 and a beta of 1.83. The business’s fifty day moving average is $14.01 and its two-hundred day moving average is $19.28.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same period in the prior year, the company earned ($1.38) EPS. The firm’s revenue was down 24.1% compared to the same quarter last year. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its stake in shares of Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after acquiring an additional 1,550 shares during the last quarter. Eastern Bank bought a new stake in Intellia Therapeutics in the third quarter valued at approximately $41,000. Values First Advisors Inc. acquired a new stake in Intellia Therapeutics in the third quarter worth $54,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after purchasing an additional 794 shares during the period. Finally, KBC Group NV grew its holdings in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after buying an additional 1,020 shares during the period. 88.77% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NTLA has been the topic of several recent research reports. Wedbush reissued a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. Barclays decreased their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Stifel Nicolaus dropped their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Finally, Robert W. Baird dropped their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.